Loading stock data…
Gyre Therapeutics (GYRE)
$6.45+0.16 (+2.54%)
After Hours$6.50+0.05 (+0.78%)· Last close Jun 29
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Gyre Therapeutics, Inc. in the Healthcare sector is trading at $6.45 with a market capitalization of $566M. Wall Street consensus targets $18.67 (3 analysts), implying a +189.4% move over the next 12 months. The stock is currently 32% below its 52-week high of $9.42, remaining 13.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +189.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $22.52M↓ | $37.20M↑ | $30.56M↑ | $26.77M↑ | $22.06M |
| Gross Profit | $21.29M↓ | $35.45M↑ | $28.94M↑ | $25.62M↑ | $21.16M |
| Operating Income | -$6.80M↓ | $120,000↓ | $6.93M↑ | $2.17M↓ | $2.27M |
| Net Income | -$8.69M↓ | -$1.72M↓ | $3.61M↑ | $442,000↓ | $2.70M |
Peer Comparison
JNJUNHPFE
Fundamentals
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$565.68M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-6.28%
Volume
Today's trading volume
79,754
Recent News
US High Growth Tech Stocks To Watch
Over the last 7 days, the United States market has risen 1.3% and over the past 12 months, it is up by an impressive 28%, with earnings forecasted to grow by 17% annually. In this robust environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and scalability in line with these positive market trends.
New Strong Sell Stocks for May 27th
GYRE, FSUN and AKZOY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2026.
Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates
Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of +16.67% and -33.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Exploring Three High Growth Tech Stocks In The US Market
Over the last 7 days, the United States market has experienced a 1.6% drop, yet it has seen a significant 15% rise over the past year, with earnings expected to grow by 16% annually. In this context of fluctuating market conditions and promising growth forecasts, identifying high-growth tech stocks involves assessing their potential for innovation and scalability within this dynamic landscape.
Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates
Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of -50.00% and +2.17%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?